The Liver Optimization Protocol: NAC + TUDCA + Milk Thistle
Your liver isn't clogged and doesn't need flushing. It needs substrate for reactions it already runs — which is why the useful protocol looks nothing like a detox tea and everything like precursor supply.
Evidence strength
Level 1a
Systematic review of RCTs
Peer-reviewed refs
8
Reading time
11 min
Key Takeaways
- Detoxification is a two-phase enzymatic process, not a flush. Phase I makes compounds reactive; phase II conjugates them — largely with glutathione — for excretion. Everything useful in this protocol supports phase II capacity.
- Build in evidence order: NAC + glycine first (the GlyNAC pair), then silymarin if metabolic markers are the concern, then TUDCA last at 250 mg.
- Formulation beats dose for milk thistle. The silybin-phosphatidylcholine complex solved silymarin's absorption problem; plain extract at any milligram count is a weaker product.
- Alcohol reduction, weight management, and treating insulin resistance outweigh every capsule here. Metabolic dysfunction is the dominant driver of fatty liver disease worldwide.
Search "liver detox" and you will be sold a tea, a two-week programme, and a story about accumulated sludge. None of that describes anything your liver does. The organ is not a filter that clogs; it is a chemical processing plant running enzymatic reactions continuously, and it does not stop and wait for a cleanse.
A critical review of detox diets found the evidence for the commercial model essentially absent. [1] That is the starting point, not a throwaway line — because once you understand what the liver is actually doing, the useful protocol writes itself, and it looks nothing like the products.
What Detoxification Actually Is
It happens in two phases.
Phase I — cytochrome P450 enzymes chemically modify fat-soluble compounds, usually by oxidation. This makes them more reactive, which is the counterintuitive part: the intermediate is often more damaging than the original compound.
Phase II — conjugation enzymes attach a water-soluble tag, most importantly glutathione, so the compound can be excreted in bile or urine.
Two things follow. First, phase II capacity is the part you can meaningfully support, and it runs on glutathione. Second, anything that pushes phase I without matching phase II support is a genuinely bad idea rather than a neutral one — it generates reactive intermediates with nowhere to go.
This is why the paracetamol case is so clarifying. Overdose depletes hepatic glutathione until reactive metabolite accumulation destroys the liver, and refilling it with acetylcysteine prevents that. [3] Phase II capacity, quite literally, is the difference between life and liver failure.
Layer 1: The Glutathione Precursors
Everything above points to the same first move: supply the raw materials for glutathione.
Glutathione is a tripeptide of cysteine, glycine, and glutamate, and cysteine is the rate-limiting ingredient. NAC supplies it. But the trial evidence points at the pair, not the single compound: a randomised clinical trial of glycine plus NAC in older adults found improvements across glutathione deficiency, oxidative stress, mitochondrial dysfunction, inflammation, physical function, and multiple aging hallmarks. [2]
Glycine is inexpensive, well tolerated, and improves sleep quality as a side effect. Leaving it out — as most liver stacks do — means fixing one of two bottlenecks.
Dose: NAC 600–1200 mg in the morning, glycine 3–5 g at night.
Layer 2: Silymarin, and Why Formulation Beats Dose
Milk thistle is the oldest liver herb and, unusually for the category, has real meta-analytic support. A systematic review and meta-analysis in NAFLD/NASH found improvement in liver markers, [4] and a separate meta-analysis of randomised trials found silymarin improved insulin resistance and sensitivity. [5]
Those two results are the same story. Metabolic dysfunction drives most fatty liver disease; a compound that improves insulin sensitivity is treating upstream of the liver finding, not just polishing an enzyme number.
The catch is absorption. Plain silymarin is poorly soluble and poorly absorbed — which is why pharmacokinetic work on the silybin–phosphatidylcholine complex showing markedly better bioavailability [6] is the single most practical fact about buying this supplement. A phytosome formulation at 420 mg beats a cheap extract at 1000 mg. Read the label for the formulation, not the number.
Dose: 420 mg silymarin daily, standardised to 70–80%, split across meals, phytosome form.
Layer 3: TUDCA, Last and Lowest
TUDCA goes last, and the ordering is deliberate.
Its mechanism is the most elegant in the stack — a chemical chaperone that eases endoplasmic reticulum stress, plus a genuine bile acid effect on pool composition. Its best human metabolic result is a four-week trial in obese adults showing improved hepatic and muscle insulin sensitivity, though notably not adipose tissue. [7]
But its outcome evidence is the thinnest of the four, and the highest-profile clinical programme built on it failed its confirmatory phase 3 trial. The full account is in the TUDCA article. Interesting mechanism, real but limited human data, appropriately last in line.
Dose: start at 250 mg with the largest meal; 500 mg if tolerated.
The Complete Protocol
| Order | Supplement | Dose | Timing | Evidence |
|---|---|---|---|---|
| 1 | NAC | 600–1200 mg | Morning, empty stomach | B |
| 2 | Glycine | 3–5 g | Evening | B |
| 3 | Milk thistle (silymarin) | 420 mg | Split with meals | B |
| 4 | TUDCA | 250–500 mg | Largest meal | C |
Add them in that order, roughly four weeks apart, so you know what is causing what. Retest ALT, AST, and GGT at 12 weeks. If those numbers started normal, be clear with yourself that you are supporting function rather than correcting a problem — and that the benefit is correspondingly harder to see.
The full step-by-step version, including interaction spacing, is in the liver protocol.
Safety: The Parts People Skip
- TUDCA is contraindicated in complete biliary obstruction, acute cholecystitis, and cholangitis — increasing bile flow is exactly wrong there. Avoid in pregnancy. Separate it from bile acid sequestrants and aluminium antacids by four hours.
- Milk thistle is remarkably safe — an updated safety review found adverse events near placebo rates [8] — but Asteraceae allergy (ragweed, daisies, chrysanthemums) rules it out, and silymarin weakly affects some drug-metabolising enzymes.
- NAC causes dose-related nausea and sulphurous burps. Split the dose or take it with food.
- Diagnosed liver disease belongs with a hepatologist. This is a protocol for normal-to-mildly-elevated enzymes, not a treatment for hepatitis, cirrhosis, or cholestasis.
What Actually Matters More Than This Protocol
It would be dishonest to end without saying it plainly. The supplements above are the smallest lever available to you.
Alcohol reduction does more for the liver than any capsule here. Weight management and insulin sensitivity do more still, because metabolic dysfunction — not toxins — is the dominant driver of fatty liver disease worldwide. Sensible paracetamol dosing prevents more liver injury than any antioxidant reverses. If you are running this protocol while drinking heavily, you have inverted the priority order, and no formulation fixes that.
Treat this stack as the nutritional layer on a foundation you have already built. That is what it is good for, and it is genuinely good for that.
Related Reading
Scientific References
- [1]Klein AV, Kiat H. Detox diets for toxin elimination and weight management: a critical review of the evidence — Journal of Human Nutrition and Dietetics (2015)Oxford 5PMID 25522674
- [2]Kumar P, Liu C, Suliburk J, et al.. Supplementing Glycine and N-Acetylcysteine (GlyNAC) in Older Adults Improves Glutathione Deficiency, Oxidative Stress, Mitochondrial Dysfunction, Inflammation, Physical Function, and Aging Hallmarks: A Randomized Clinical Trial — Journals of Gerontology Series A (2023)Oxford 1bPMID 35975308
- [3]Chiew AL, Gluud C, Brok J, et al.. Interventions for paracetamol (acetaminophen) overdose — Cochrane Database of Systematic Reviews (2018)Oxford 1aPMID 29473717
- [4]Li S, Duan F, Li S, et al.. Administration of silymarin in NAFLD/NASH: A systematic review and meta-analysis — Annals of Hepatology (2024)Oxford 1aPMID 38579127
- [5]Yin S, Zhu F, Liu Y, et al.. Effects of silymarin on insulin resistance and sensitivity: A systematic review and meta-analysis of randomized controlled trials — Diabetes Research and Clinical Practice (2025)Oxford 1aPMID 39855603
- [6]Barzaghi N, Crema F, Gatti G, et al.. Pharmacokinetic studies on IdB 1016, a silybin-phosphatidylcholine complex, in healthy human subjects — European Journal of Drug Metabolism and Pharmacokinetics (1990)Oxford 2bPMID 2088770
- [7]Kars M, Yang L, Gregor MF, et al.. Tauroursodeoxycholic Acid may improve liver and muscle but not adipose tissue insulin sensitivity in obese men and women — Diabetes (2010)Oxford 2bPMID 20522594
- [8]Soleimani V, Delghandi PS, Moallem SA, et al.. Safety and toxicity of silymarin, the major constituent of milk thistle extract: An updated review — Phytotherapy Research (2019)Oxford 5PMID 31069872
Related protocols
Partner with BiohackingHub
Editorial placements, sponsorships, and product features for evidence-minded brands.